Quick Detail:
1. Product Name: Letrozole Anti Estrogen Steroids Powder Supplements for Men Femara side effects
2. Molecular Formula: C17H11N5
3. Molecular Weight: 285.3
4. CAS No.: 112809-51-5
6. Melting Point : 181-183°C
7. Appearance: White powder or crystal powder
8.
9. Packing: As customers requirments
10. Usage: for postmenopausal women with advanced breast cancer, second-line therapy for the treatment of multiple anti-estrogen therapy after failure, for bodybuilders used as AI in post cycle
How to take Femara?
Femara is usually taken once per day, or once every other day. Follow all directions on your prescription label. Do not take this medicine in larger or smaller amounts or for longer than recommended.
You may take this medicine with or without food.
While using Femara, you may need frequent blood tests. Your bone mineral density may also need to be checked.
Store at room temperature away from moisture and heat.
What should I avoid while taking Femara?
This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.
This medicine can pass into body fluids (including urine, feces, vomit, semen, vaginal fluid). Patients and caregivers should wear rubber gloves while cleaning up body fluids, handling contaminated trash or laundry or changing diapers. Wash hands before and after removing gloves. Wash soiled clothing and linens separately from other laundry.
Description:
1. Letrozole is an oral non-steroidal inhibitor for the treatment of hormonally-responsive breast cancer after surgery. |
2. Letrozole prevents the aromatase from producing estrogens by competitive, reversible binding to the heme of its cytochrome p450 unit, the action is specific,and letrozol does not reduce production of mineralo-or corticosteroids. |
3. Letrozole lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body. |
4. Letrozole is used to treat breast cancer in postmenopausal women. It is often given to women who have been taking tamoxifen (Nolvadex, Soltamox) for 5 years. |
Applications:
Femara(generic name is letrozole) is a new drug developed for the treatment of advanced breast cancer in women. Femara is the second in a new class of third-generation selective oral aromatase inhibitors.
It acts by blocking the enzyme aromatase, subsequently blocking the production of estrogen. Since many forms of breast cancer cells are stimulated by estrogen, it is hoped that by reducing amounts of estrogen in the body the progression of such a disease can be halted. This is the basic premise behind Nolvadex, except this drug blocks the action and not production of estrogen.
The effects of Femara can be quite dramatic to say the least. A daily dose of one tablet (2.5 mg) can produce estrogen suppression greater than 80 % in treated patients. With the powerful effect this drug has on hormone levels, it is only to be used (clinically) by post-menopausal women whose disease has progressed following treatment with Nolvadex. Side effects like hot flushes and hair thinning can be present, and would no doubt be much more severe in pre-menopausal patients.
When used with strong, readily aromatizing androgens such as Dianabol or testosterone, gynecomastia and water retention can be effectively blocked. In combination with Propecia (finasteride), we have a great advance.
With the one drug halting estrogen conversion and the other blocking 5-alpha reduction (testosterone, methyltestosterone and Halotestin only), related side effects can be effectively minimized. Here the strong androgen testosterone could theoretically provide incredible muscular growth, while at the same time being as tolerable as nandrolone.
Additionally the quality of the muscle should be greater, the athlete appearing harder and much more defined without holding excess water.
Specifications:
Tests | Specifications | Results |
Appearance | White or off-white crystaline powder |
White |
Solubility |
Soluble in Chloroform; |
Conform |
ldentification |
(1)Maximum absorption in wavelength of 240 nm |
Conform |
(2)Infrared spectrum should be in accordance the dominant peak of contrast | In accordance with the dominant peak of contrast | |
Melting points | 182℃-184℃ | 182℃ |
Related substances | ≤0.5% | 0.3% |
Single impurity | ≤0.3% | 0.2% |
Loss on drying | ≤1.0% | 0.8% |
[Assay]C17H11N5 |
≥98.0% | 99.2% |
Conclusion | Conforms Specifications of Enterprise Standard. |